Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
SPRO
vs
S&P 500
SPRO
S&P 500
Over the past 12 months, SPRO has underperformed S&P 500, delivering a return of -57% compared to S&P 500's +11% growth.
Stocks Performance
SPRO vs S&P 500
Performance Gap
SPRO vs S&P 500
Performance By Year
SPRO vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Spero Therapeutics Inc
Glance View
Spero Therapeutics is a biotechnology company that develops medicines for hard-to-treat bacterial infections, with a focus on infections caused by drug-resistant Gram-negative bacteria. Its work centers on antibiotic candidates designed to be taken by mouth or given in other convenient ways, so they can treat serious infections that often require hospital care. The company is not a mass drug seller today; it is mainly a research and development business. Its customers are ultimately patients and the doctors and hospitals that treat them, but its money comes from drug development partnerships, licensing deals, grants, and, if its medicines win approval, future product sales or royalty income. What makes Spero’s business model different is that it sits in a narrow part of the pharmaceutical chain: it tries to create new antibiotics where resistance has made older drugs less useful. That means its value depends less on broad consumer demand and more on whether its drug candidates can clear clinical testing, gain regulatory approval, and earn a place in hospital infection treatment.
